Abstract
Genome-wide association studies (GWAS) have identified more than 75 genetic risk loci for Alzheimer’s Disease (AD), however for a substantial portion of these loci the genetic variants or genes directly involved in AD risk remain to be found. A GWAS locus defined by the index SNP rs1476679 in ZCWPW1 is one of the largest AD loci as the association signal spans 56 potential risk genes. The three most compelling candidate genes in this locus are ZCWPW1, PILRA and PILRB, based on genetic, transcriptomic, and proteomic evidence. We performed amplicon-based target enrichment and next-generation sequencing of the exons, exon-intron boundaries, and UTRs of ZCWPW1, PILRA and PILRB on an Illumina MiSeq platform in 1048 Flanders-Belgian late-onset AD patients and 1037 matched healthy controls. Along with the single-marker association testing, the combined effect of Sanger-validated rare variants was evaluated in SKAT-O. No common variants (n = 40) were associated with AD. We identified 20 validated deleterious rare variants (MAF < 1%, CADD score ≥ 20), 14 of which in ZCWPW1. This included 4 predicted loss-of-function (LoF) mutations that were exclusively found in patients (P = 0.011). Haplotype sharing analysis revealed distant common ancestors for two LoF mutations. Single-molecule long-read Nanopore sequencing analysis unveiled that all LoF mutations are phased with the risk haplotype in the locus. Our results support the recent report for the role of ultra-rare LoF ZCWPW1 variants in AD and suggest a potential risk mechanism for AD through ZCWPW1 haploinsufficiency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research was funded in part by the Alzheimer Research Foundation (SAO-FRA), the Research Foundation Flanders (FWO), and the University of Antwerp Research Fund, Belgium. FK is a supported by a PhD fellowship from the University of Antwerp Research Fund. This work was supported in part by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Programme - Neurodegenerative Disease Research (JPND). Inserm UMR1167 is also funded by Inserm, Institut Pasteur de Lille, the Lille Métropole Communauté Urbaine, the French government's LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer's disease).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants and/or their legal guardian signed written informed consent forms before inclusion. The study protocols were approved by the ethics committees of the Antwerp University Hospital and the University of Antwerp, and the ethics committees of the participating neurological centers of the BELNEU consortium.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵$ The following members of the BELNEU Consortium have contributed to the clinical and pathological phenotyping and follow-up of the Belgian patient cohorts: Johan Goeman, Roeland Crols (Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium); Dirk Nuytten (Hospital Network Antwerp (ZNA) Stuivenberg, Antwerp, Belgium); Rudy Mercelis (Antwerp University Hospital, Edegem); Mathieu Vandenbulcke (University of Leuven and University Hospitals Leuven, Leuven, Belgium); Anne Sieben, Jan L. De Bleecker, Patrick Santens (University Hospital Ghent, Ghent, Belgium); Jan Versijpt, Alex Michotte (University Hospital Brussels, Brussels, Belgium); Olivier Deryck, Ludo Vanopdenbosch, Bruno Bergmans (AZ Sint-Jan Brugge, Bruges, Belgium); Christiana Willems, Nina De Klippel (Jessa Hospital, Hasselt, Belgium); Jean Delbeck (General Hospital Sint-Maria, Halle); Adrian Ivanoiu (Saint-Luc University Hospital, Université Catholique de Louvain, Louvain-la-Neuve, Belgium); and Eric Salmon (University of Liege and Memory Clinic, CHU Liege, Liege, Belgium).
Data Availability
To comply with EU law and participant privacy, individual-level clinical and genetic data cannot be shared publicly, however summary statistics for single marker genetic association and gene-based rare variant association analyses can be found in the manuscript and the supplementary tables.
